Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis

Osteoarthritis (OA) is a degenerative joint disease that causes pain and bone deterioration driven by an increase in prostaglandins (PGs) and inflammatory cytokines. Current treatments focus on inhibiting prostaglandin production, a pro-inflammatory lipid metabolite, with NSAID drugs; however, other...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Cindy B. McReynolds, Sung Hee Hwang, Jun Yang, Debin Wan, Karen Wagner, Christophe Morisseau, Dongyang Li, William K. Schmidt, Bruce D. Hammock
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2019-05-01
Saila:Frontiers in Pharmacology
Gaiak:
soluble epoxide hydrolase
osteoarthritis
epoxyeicostrienoic acids
analgesic
non-opioid analgesic
non-NSAID analgesic
Sarrera elektronikoa:https://www.frontiersin.org/article/10.3389/fphar.2019.00533/full
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak